Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC13A5 | Q86YT5 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071793 | 1.00 | SLC13A5 (0.49) | SLC13A5KDM4EMEN1LMNACYP1A2 | |
| SCHEMBL6696645 | 1.00 | SLC13A5 (0.49) | SLC13A5KDM4EMEN1LMNACYP1A2 | |
| Ethyl Acetate SCHEMBL6494884 | 0.89 | ALDH1A1 (0.43) | SLC13A5KDM4EMEN1LMNACYP1A2 | |
| SCHEMBL4075370 | 0.88 | MMP12 (0.42) | SLC13A5KDM4EMEN1LMNACYP1A2 | |
| SCHEMBL4075367 | 0.88 | MMP12 (0.42) | SLC13A5KDM4EMEN1LMNACYP1A2 | |
| SCHEMBL11483933 | 0.86 | TDP1 (0.43) | KEAP1HPGDADRA1ASLC6A3ALDH1A1 | |
| SCHEMBL6560435 | 0.84 | CA12 (0.43) | SLC13A5KDM4ELMNAHPGDHDAC3 | |
| Phenylpropanolamine SCHEMBL6905819 | 0.84 | LMNA (0.48) | SLC13A5KDM4EMEN1LMNACYP1A2 | |
| SCHEMBL4074798 | 0.83 | PPID (0.46) | SMN1; SMN2 | |
| SCHEMBL27538796 | 0.83 | HDAC3 (0.54) | KDM4EMEN1LMNACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481961-B1 | PROCESS FOR PRODUCING (R)-3-HYDROXY-3-(2-PHENYLETHYL)HEXANOIC ACID AND ITS INTERMEDIATE | SUMITOMO CHEMICAL CO (JP) | 2009-11-25 | — | — | EP | claimed |
| EP-1894912-A1 | Process for producing racemic 3-hydroxy-3-(2-phenylethyl) hexanoic acid ester | Sumitomo Chemical Company, Limited (JP) | 2008-03-05 | — | — | EP | claimed |
| CN-1301244-C | Process for producing -3-hydroxy-3- (2-phenylethyl) hexanoic acid and intermediates thereof | SUMITOMO CHEMICAL CO (JP) | 2007-02-21 | — | — | CN | claimed |
| CN-1284763-C | Novel intemediate for preparing 4-hydroxy-2-oxygen-pyran derivatives as protease inhibitor | PHARMACIA & UPJOHN CO LLC (US) | 2006-11-15 | — | — | CN | claimed |
| CN-1617846-A | Process for producing -3-hydroxy-3- (2-phenylethyl) hexanoic acid and intermediates thereof | SUMITOMO CHEMICAL CO (JP) | 2005-05-18 | — | — | CN | claimed |
| EP-1481961-A1 | PROCESS FOR PRODUCING (R)-3-HYDROXY-3-(2-PHENYLETHYL)HEXANOIC ACID AND ITS INTERMEDIATE | Sumitomo Chemical Company, Limited (JP) | 2004-12-01 | — | — | EP | claimed |
| US-20040138496-A1 | Production method of (R)-3- hydroxy-3-(2-phenylethyl)hexanoic acid and intermediate thereof | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2004-07-15 | — | — | US | claimed |
| CN-1511820-A | Novel intemediate for preparing 4-hydroxy-2-oxygen-pyran derivatives as protease inhibitor | �������Ŷ���Լ��������˾ | 2004-07-14 | — | — | CN | claimed |
| WO-2004052883-A2 | PROCESS FOR THE SEPARATION OF ENANTIOMERS | HONEYWELL INTERNATIONAL INC. (US) | 2004-06-24 | — | — | WO | claimed |
| US-20040110957-A1 | Process for the synthesis of an antiviral compound | HONEYWELL INTERNATIONAL, INC. (US) | 2004-06-10 | — | — | US | claimed |
| EP-1015441-B1 | PROCESS TO PRODUCE 4-HYDROXY-2-OXO-PYRANE DERIVATIVES USEFUL AS PROTEASE INHIBITORS | UPJOHN CO (US) | 2004-05-12 | — | — | EP | claimed |
| US-6683207-B2 | RESOLUTION USING 1-AMINO-1-PHENYLETHANE DERIVATIVE | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2004-01-27 | — | — | US | claimed |
| US-20030176507-A1 | Production method of (R) -3 hydroxy-3- (2-phenylethyl) hexanoic acid and intermediate thereof | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2003-09-18 | — | — | US | claimed |
| US-6265604-B1 | AS PROTEASE INHIBITOR USEFUL IN TREATING HUMANS INFECTED WITH THE HIV VIRUS | PHARMACIA & UPJOHN COMPANY | 2001-07-24 | — | — | US | claimed |
| CN-1268947-A | Novel process for preparing 4-hydroxy-2-oxo-pyran derivatives as protease inhibitors | UPJOHN CO (US) | 2000-10-04 | — | — | CN | claimed |
| EP-1481961-B1 | PROCESS FOR PRODUCING (R)-3-HYDROXY-3-(2-PHENYLETHYL)HEXANOIC ACID AND ITS INTERMEDIATE | SUMITOMO CHEMICAL CO (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-1481961-B1 | PROCESS FOR PRODUCING (R)-3-HYDROXY-3-(2-PHENYLETHYL)HEXANOIC ACID AND ITS INTERMEDIATE | SUMITOMO CHEMICAL CO (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-1015441-A1 | PROCESS TO PRODUCE 4-HYDROXY-2-OXO-PYRANE DERIVATIVES USEFUL AS PROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| US-6077963-A | Process to produce a protease inhibitor | PHARMACIA & UPJOHN COMPANY (US) | 2000-06-20 | — | — | US | disclosed |
| WO-1999012919-A1 | PROCESS TO PRODUCE 4-HYDROXY-2-OXO-PYRANE DERIVATES USEFUL AS PROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138496-A1 | Production method of (R)-3- hydroxy-3-(2-phenylethyl)hexanoic acid and intermediate thereof | HAAO, HPD, HAO2 | SLC13A5 403/4885KDM4E 2546/4885MEN1 4186/4885 |
| US-20040110957-A1 | Process for the synthesis of an antiviral compound | EIF2AK2, IRF3, RTF1 | SLC13A5 4125/4885KDM4E 1241/4885MEN1 4842/4885 |
| US-20030176507-A1 | Production method of (R) -3 hydroxy-3- (2-phenylethyl) hexanoic acid and intermediate thereof | HAAO, HPD, HAO2 | SLC13A5 586/4885KDM4E 2381/4885MEN1 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.